Chroniques génomiques - 23andMe ou comment (très bien) valoriser ses clients

Abstract

The announcement of several deals between the DTC genetics firm 23andMe and Genentech, Pfizer and other corporations reveals the real business model of the company: selling access to sets of characterized patients for targeted drug development. This may be a useful strategy, but it raises a number of questions concerning the privacy of the company’s customers and also of adequate compensation when they become valuable currency.